Seth Loring Harrison
CIK 1404955 · last filed 2026-07-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
HTWR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
NEW YORK, NY 10169
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| STOK | Director | 17,161,713 | $27.73 | $475.89M | $39.63M | 11 | 2026-07-17 |
| Akero Therapeutics, Inc. (AKRO) Delisted | Director | 0 | $54.65 | $0 | $14.28M | 13 | 2025-12-09 |
| HeartWare International, Inc. (HTWR) Delisted | Director | 0 | — | — | -$111.36M | 31 | 2016-08-24 |
| Eledon Pharmaceuticals, Inc. (TKAI) Delisted | Director | 902,753 | — | — | $5.44M | 3 | 2016-06-16 |
Recent Filings · Page 2 of 7
70 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-11-01 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −44,103 | -$1.78M | EDGAR |
| 2022-10-27 | Akero Therapeutics, Inc. (AKRO) Delisted | Sell (S) | −285,487 | -$12.19M | EDGAR |
| 2022-06-08 | STOK | Grant (A) | — | $0 | EDGAR |
| 2022-06-03 | Akero Therapeutics, Inc. (AKRO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-25 | STOK | Grant (A) | — | $0 | EDGAR |
| 2021-06-03 | Akero Therapeutics, Inc. (AKRO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-11-25 | STOK | Buy (P) | +375,000 | $14.62M | EDGAR |
| 2020-07-14 | Akero Therapeutics, Inc. (AKRO) Delisted | Buy (P) | +415,000 | $14.94M | EDGAR |
| 2020-06-05 | STOK | Grant (A) | — | $0 | EDGAR |
| 2020-06-02 | Akero Therapeutics, Inc. (AKRO) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.